Tag: Vesper Duo
Duo venous stent system shows 90.2% primary patency at 12 months,...
The Duo venous stent system (Vesper Medical/Philips) showed a 98.7% freedom from major adverse events (MAEs) at 30 days and 90.2% primary patency at...
Vesper Medical acquisition adds key piece to Philips’ venous portfolio
Bert van Meurs, the chief business leader for Image Guided Therapy with Royal Philips, speaks to Venous News following the company’s acquisition of Vesper...
Vesper Medical announces completion of enrolment in the VIVID trial
Vesper Medical recently announced the completion of enrolment in its pivotal study—VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper...
Vesper DUO Venous Stent System may remove the need to “mix...
Mahmood Razavi (Orange, USA) speaks to Venous News about the recently initiated VIVID trial – a prospective, multicentre, single-arm study which has just begun enrolment and is designed...
Vesper Medical announces first enrolment in the VIVID trial
Vesper Medical recently announced initiation of its US Food and Drug Administration (FDA) investigational device exemption (IDE) study—VIVID (Venous stent for the iliofemoral vein investigational...
Vesper Medical announces US$37 million financing with Vensana Capital and Gilde...
Vesper Medical, a developer of medical devices for minimally invasive peripheral vascular procedures, has announced a US$37 million financing with Vensana Capital and Gilde...
Vesper Medical completes US$10.5m Series A financing
Vesper Medical, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, has announced that it completed its Series A financing, totaling...